Roche and Gilead Sciences launched a Phase III clinical trial in severe COVID-19 pneumonia, testing Roche’s Actemra/RoActemra with Gilead’s remdesivir.
Patients given the malaria drug touted by President Donald Trump as a potential treatment for COVID-19 did not improve significantly over those who did not, according to two new studies published in the medical journal BMJ .
GlaxoSmithKline started a trial to test an experimental rheumatoid arthritis drug on patients suffering from COVID-19 related pneumonia.
Italian researchers are looking at whether a higher than usual number of cases of severe pneumonia and flu in Lombardy in the last quarter of 2019 may be a signal that the new coronavirus might have spread beyond China earlier than previously thought.
Days after Roche began shipping hundreds of thousands of the Swiss pharma giant’s recently approved COVID-19 test to laboratories in the United States, the company initiated a late-stage trial assessing the rheumatoid arthritis drug Actemra in patients who have severe COVID-19 caused pneumonia.
The U.S. Centers for Disease Control and Prevention (CDC) confirmed a second U.S. case of the new coronavirus from China in a Chicago woman, and said as many as 63 potential cases were being investigated as the sometimes deadly illness continues to spread around the globe.
Doctors studying lung tissue from people with vaping-related injuries have ruled out one diagnosis as a probable explanation of how vaping harms the lungs, further deepening the mystery over the exact cause of hundreds of illnesses in the United States.
Shionogi & Co. Ltd. announced results from APEKS-NP, an international, double-blind, randomized Phase III clinical trial evaluating the efficacy and safety of the investigational antibiotic cefiderocol in patients with nosocomial pneumonia (NP).
The U.S. FDA approved Merck’s supplemental New Drug Application for the use of Zerbaxa for the treatment of patients 18 years and older with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by certain susceptible Gram-negative microorganisms.
In GlaxoSmithKline’s first-quarter 2019 report was an announcement that the global pharma giant cut the development of two vaccine programs – one for strep pneumonia and the other for a universal flu vaccine.